Current perspectives on primary prophylaxis and patient risk factors for venous thromboembolism in the cancer patient

Cancer Control

Volumn 12, Issue SUPPL. 1, 2005, Pages 11-16

  Liebman, Howard A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTICOAGULANT AGENT; BEVACIZUMAB; DALTEPARIN; ENOXAPARIN; FLUOROURACIL; FOLINIC ACID; FONDAPARINUX; HEPARIN; IRINOTECAN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT ERYTHROPOIETIN; TAMOXIFEN; THALIDOMID; THALIDOMIDE; WARFARIN;

ADVANCED CANCER; BLEEDING; BREAST CANCER; CANCER PATIENT; CLINICAL TRIAL; COLON CANCER; DRUG INDICATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; MULTIPLE MYELOMA; REVIEW; RISK FACTOR; THROMBOSIS; UTERINE CERVIX CANCER; VAGINA CANCER; VENOUS THROMBOEMBOLISM;

EID: 25144515351     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/1073274805012003s03     Document Type: Review

References (62)

1. Hawkins D. Pharmacoeconomics of thrombosis management. Pharmacotherapy. 2004:24(7 pt 2):95S-99S.
2. Lee AY. Epidemiology and management of venous thromboembolism in patients with cancer. Thromb Res. 2003;110:167-172.
3. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107:I17-I21.
4. Gouin-Thibaut I, Samama MM. Venous thrombosis and cancer [in French]. Ann Biol Clin (Paris). 2000;58:675-682.
5. Levesque H, Belizna C, Michel P, et al. Venous thromboembolic treatment in patients with cancer [in French]. Rev Med Interne. 2004;25:906-914.
6. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585-593.
7. Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715-722.
8. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patents with solid tumors: determination of frequency and characteristics: Thromb Haemost. 2002;87:575-579.
9. Ambrus JL, Ambrus CM, Mink IB, et al. Causes of death in cancer patients. J Med. 1975;6:61-64.
10. Shen VS, Pollak EW. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J. 1980;73:841-843.
11. Desai AA, Vogelzang NJ, Rini BI, et al. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer. 2002;95:1629-1636.
12. Zangari M, Saghafifar F, Anaissie E, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis. 2002;13:187-192.
13. Zangari M, Anaissie E, Bariogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614-1615.
14. Agnelli G. Prevention of venous thromboembolism in surgical patients. Circulation. 2004;110(24suppl 1):IV4-IV12.
15. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809-815.
16. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine. 1999;78:285-291.
17. Mortimer JE, Urban JH. Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents. Oncology (Huntingt). 2003;17: 652-659.
18. Weitz IC, Israel VK, Liebman HA. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer. 1997; 79:2024-2027.
19. Oberhoff C, Szymeczek J, Hoffmann O, et al. Adjuvant antiestrogen treatment with tamoxifen in postmenopausal women with breast cancer: a longitudinal study of blood coagulation and fibrinolysis. Breast Cancer Res Treat. 1998;50:73-81.
20. Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer. 2004;101:439-449.
21. Pelerin D, Silvestre RM, Jerusalem G, et al. How I manage patients developing thromboembolic complications as a result of breast cancer treatment with tamoxifen [in French]. Rev Med Liege. 2002;57:755-756.
22. Goodnough LT, Safto H, Manni A, et al. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen: a study of 159 patients. Cancer. 1984;54:1264-1268.
23. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988;318: 404-407.
24. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991;9: 286-294.
25. Oztop I, Demirkan B, Yaren A, et al. Rapid tumor lysis syndrome in a patient with metastatic colon cancer as a complication of treatment with 5-fluorouracil/leucoverin and irinotecan. Tumori. 2004;90:514-516.
26. Mizushima T, Sando K, lto T, et al. A case of advanced colon cancer responding completely to systemic 5-fluorouracil/1-leucovorin therapy [in Japanese]. Gan To Kagaku Ryoho. 2004;31:2047-2049.
27. Arkenau HT, Rettig K, Forschen R. Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusionfleuoovorin versus high-dose 5-fluorouracil 24-h infusion. Int J Cotorectal Dis. 2005;20:258-261.
28. Adjuvant chemotherapy with oxaliplatin, in combination with fluorouracil plus leucovorin prolongs disease-free survival, but causes more adverse events in people with stage II or III colon cancer. Abstracted from Andre T, Boni C, Mounedji-Boudiaf L, et al. Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351.
29. Cancer Treat Rev. 2004;30:711-713.
30. Minnema MC, Breitkreutz I, Auwerda JJA, et al. Prevention of venous thromboembolism with low-molecular weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia. 2004;18: 2044-2046.
31. Zangari M, Bariogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effect of prophylactic and therapeutic anticoagulation. Br J Haematol. 2004; 126:715-721.
32. Steurer M, Sudmeier I, Stauder R, et al. Thromboembolic events in patients with myelodysplastte syndrome receiving thalidomide in combination with darbepoetin-alpha. Br J Haematol. 2003;121:101-103.
33. Kropff MH, Lang N, Bisping G, et al. Hyperfractionated cyclophosphamide in combination with pulsed Dexamethasone and thalidomide (Hyper-CDT) in primary refractory or relapsed multiple myeloma. Br J Haematol. 2003; 122:607-616.
34. Home MK, Figg WD, Arien P, et al. Increased frequency of venous thromboembolism with combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer. Pharmacotherapy. 2003; 23:315-318.
35. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;2335-2342.
36. Wun T, Law L, Harvey D, et al. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer. 2003;98:1514-1520.
37. Kakkar AK, Levine M, Pinedo HM, et al. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist. 2003;8:381-388.
38. ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg. 1997;84:1099-1103.
39. Bergqvist D, Burmark US, Flordal PA, et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patients. Br J Surg. 1995;82:496-501.
40. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg. 1988;208:227-240.
41. Gallus AS. Anticoagulants in the prevention of venous thromboembolism. Baillieres Clin Haematol. 1990;3:651-684.
42. Zhai ZG, Wang C, Liu YM, et al. Comparison of unfractionated heparin and low molecular weight heparin in pulmonary thromboembolism: meta-analysis [in Chinese]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2004;26:221-226.
43. Rasmussen MS. Does prolonged thromboprophylaxis improve outcome in patients undergoing surgery? Cancer Treat Pev. 2003;29(suppl 2):15-17.
44. Bergqvist D. Venous thromboembolism in cancer patients: expanding horizons. Semin Thromb Hemost. 2002;28(suppl 3):19-23.
45. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346:975-980.
46. Leizorovicz A, Cohen AT, Turpie AGG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874-879.
47. Bauersachs RM. Fondaparinux: an update on new study results. Eur J Clin invest. 2005;35(suppl 1):27-32.
48. Alikhan R, Cohen AT, Combe S, et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis. 2003;14:341-346.
49. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost. 2003;1: 1906-1913.
50. Mismetti P, Laporte S, Darmon JY, et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 2001;88:913-930.
51. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994;343:886-889.
52. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-153.
53. Guyatt G, Schunemann HJ, Cook D, et al. Applying the grades of recommendation for antithrombotic and thrombolytic therapy. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):179S-187S.
54. Rasmussen MS. Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged thromboprophylaxis. Cancer Treat Rev. 2002;28:141-144.
55. Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters: a randomized prospective trial. Ann Intern Med. 1990;112:423-428.
56. Klerk CP, Smorenburg SM, Büller HR. Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review. Arch Intern Med 2003;163:1913-1921.
57. Boraks P, Seale J, Price J, et al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br J Haematol. 1998;101;483-486.
58. Rosovsky RP, Kuter DJ. Catheter-related thrombosis in cancer patients: pathophysiology, diagnosis, and management. Hematol Oncol Clin North Am. 2005;19:183-202.
59. Magagnoli M, Ćastagna L, Masci G, et al. Low-dose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with 5-fiuorouracil-based chemotherapy? Oncologist. 2004;9:594-595.
60. Knovich MA, Lesser GJ. The management of thromboembolic disease in patients with central nervous system malignancies. Curr Treat Options Oncol. 2004;5:511-517.
61. Goldhaber SZ, Dunn K, Gerhard-Herman M, et al. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest. 2002;122:1933-1937.
62. McLeod RS, Geerts WH, Sniderman KW, et al. Canadian Colorectal Surgery DVT Prophylaxis Trial investigators. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery. Results of the Canadian Colorectal DVT Prophylaxis Trial: a randomized, double-blind trial. Ann Surg. 2001;233:438-444.